The role of radiotherapy in epithelial ovarian cancer: a literature overview
Ovarian cancer (OC) accounts for 3% of all cancer in women and for 5% of all cancer-related deaths. Epithelial Ovarian Cancer (EOC) is a radiosensitive malignancy with a poor prognosis. In the pre-chemotherapy era, radiation therapy (RT) delivered to the abdominopelvic region (whole abdominal irradiation, WAI) has historically played a role in the adjuvant and consolidation setting. Specific cluster of patients with early-stage disease and definite histologies may take advantage of RT. Platinum-based chemotherapy (CT) has replaced RT and plays a major role in most of the clinical settings. Radiation Therapy for palliation is recommended in patients with localized symptoms. Nevertheless, modern RT represents a reliable treatment option, with a mild toxicity profile, particularly effective for oligo-recurrent or progressive disease. The present literature review aims to highlight the historical role of RT in EOC, the actual lines of evidence, and the future perspectives.
KeywordsEpithelial ovarian cancer Radiotherapy Radiation Stereotactic ablative radiotherapy
Compliance with ethical standards
Conflict of interest
We declare that we do not have any conflict of interest.
The present study has been reviewed and approved by the Internal Review Board of the Department of Oncology of the University of Turin at AOU Citta’ della Salute e della Scienza, Turin, Italy.
Research involving human and animal participants
No human participants were involved in the present study.
- 17.Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerualth A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol. 1988;6:1254–63.CrossRefGoogle Scholar
- 29.Sorbe B. Swedish-Norgewian Ovarian Cancer Study G: consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13:278–86.CrossRefGoogle Scholar
- 30.Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, et al. Intra- peritoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849–55.CrossRefGoogle Scholar
- 33.Arians N, Kieser M, Benner L, Rochet N, Katayama S, Sterzing F, et al. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III): first results of a prospective phase 2 study. Int J Radiat Oncol Biol Phys. 2017;99:912–20.CrossRefGoogle Scholar
- 39.Franco P, De Bari B, Ciammella P, Fiorentino A, Chiesa S, Amelio D, et al. The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO – Young Members Working Group (AIRO Giovani). Tumori. 2014;100:e214–9.CrossRefGoogle Scholar
- 41.Kunos C, Brindle JM, Debernardo R. Stereotactic radiosurgery for gynecologic cancer. J Vis Exp. 2012;62:3793.Google Scholar
- 42.Stereotactic body radiation therapy in treating patients with recurrent primary ovarian or uterine cancer. ClinicalTrials.gov Identifier (NCT number): NCT03325634.Google Scholar
- 49.Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.CrossRefGoogle Scholar
- 52.PDL-1 inhibition and focal sensitizing radiotherapy in recurrent ovarian/primary peritoneal/fallopian tube cancers. ClinicalTrials.gov Identifier (NCT Number): NCT03283943.Google Scholar
- 53.Durvalumab, Tremelimumab + Radiotherapy in gynecologic cancer. ClinicalTrials.gov Identifier (NCT Number): NCT03277482.Google Scholar